Millennium Management LLC Buys Shares of 374,509 Emergent Biosolutions Inc (NYSE:EBS)

Millennium Management LLC purchased a new position in Emergent Biosolutions Inc (NYSE:EBS) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 374,509 shares of the biopharmaceutical company’s stock, valued at approximately $19,579,000. Millennium Management LLC owned approximately 0.73% of Emergent Biosolutions at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the business. Usca Ria LLC bought a new position in shares of Emergent Biosolutions during the 3rd quarter valued at about $35,000. Quadrant Capital Group LLC raised its holdings in Emergent Biosolutions by 1,510.2% during the 3rd quarter. Quadrant Capital Group LLC now owns 789 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 740 shares during the period. Rehmann Capital Advisory Group lifted its stake in Emergent Biosolutions by 303.9% in the second quarter. Rehmann Capital Advisory Group now owns 1,034 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 778 shares in the last quarter. Private Capital Group LLC lifted its stake in Emergent Biosolutions by 11.1% in the second quarter. Private Capital Group LLC now owns 2,397 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 239 shares in the last quarter. Finally, KBC Group NV acquired a new position in shares of Emergent Biosolutions in the second quarter valued at approximately $126,000. Institutional investors own 86.61% of the company’s stock.

In other Emergent Biosolutions news, Director Kathryn C. Zoon sold 1,000 shares of Emergent Biosolutions stock in a transaction on Monday, November 18th. The shares were sold at an average price of $54.06, for a total value of $54,060.00. Also, Director Kathryn C. Zoon sold 3,082 shares of Emergent Biosolutions stock in a transaction on Friday, November 8th. The shares were sold at an average price of $54.15, for a total transaction of $166,890.30. Following the completion of the sale, the director now owns 18,412 shares in the company, valued at $997,009.80. The disclosure for this sale can be found here. Insiders sold 5,591 shares of company stock worth $305,635 over the last quarter. 14.10% of the stock is owned by corporate insiders.

Shares of Emergent Biosolutions stock opened at $53.66 on Wednesday. The firm has a market cap of $2.83 billion, a PE ratio of 23.03, a P/E/G ratio of 0.89 and a beta of 1.50. The business’s 50 day simple moving average is $54.88 and its 200 day simple moving average is $48.56. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.71 and a current ratio of 2.54. Emergent Biosolutions Inc has a 52-week low of $39.11 and a 52-week high of $73.88.

Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $1.21 earnings per share for the quarter, topping analysts’ consensus estimates of $0.63 by $0.58. The firm had revenue of $311.80 million during the quarter, compared to the consensus estimate of $289.16 million. Emergent Biosolutions had a return on equity of 10.05% and a net margin of 0.42%. The business’s revenue was up 79.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.55 EPS. As a group, equities research analysts predict that Emergent Biosolutions Inc will post 3.08 EPS for the current year.

EBS has been the subject of several research reports. Cowen reissued a “hold” rating and set a $67.00 price objective on shares of Emergent Biosolutions in a research report on Monday, November 25th. Guggenheim began coverage on shares of Emergent Biosolutions in a research report on Thursday, September 12th. They issued a “buy” rating and a $65.00 price objective on the stock. Laidlaw set a $72.00 target price on shares of Emergent Biosolutions and gave the stock a “buy” rating in a research note on Wednesday, September 4th. Wells Fargo & Co reaffirmed a “buy” rating on shares of Emergent Biosolutions in a research note on Thursday, November 7th. Finally, TheStreet upgraded Emergent Biosolutions from a “c” rating to a “b” rating in a report on Wednesday, November 6th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Emergent Biosolutions has a consensus rating of “Buy” and an average price target of $69.00.

About Emergent Biosolutions

Emergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids.

Featured Article: Monthly Dividend Stocks Can Provide Solid Income

Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit